Efficacy of Mindfulness-based Mobile Application Use in Patients With Depressive Disorder

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05060393

Enrollment

140

Registered

2021-09-29

Start date

2021-05-01

Completion date

2023-01-01

Last updated

2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The presented randomized-controled study aim to assess the use of internet-based mindfulness intervention via mobile application for 30 days in patients with Major Depressive Disorder (MDD)

Detailed description

Mindfulness-based interventions (MBI) proved to be effective in relapse prevention in MDD. Next, MBI in form of free mobile applications can be an effective augmentation of the treatment as usual (TAU) and can fill a gap in the ambulatory care. Given this background, the aim of this randomized controlled study is to assess the effectiveness of additional MBI via mobile app on the symptom severity and stress levels, compared to TAU.

Interventions

BEHAVIORALMindfulness-based cognitive therapy

Mobile application, mindfulness-based therapy

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Depression, current ill

Exclusion criteria

* acute alcohol- and drug dependency, schizophrenia or psychotic disorder, severe somatic illnes, not having smartphone or not willing to use mobile application

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline self reported Depression Severity	30 days	Beck Depression Inventory
Change from Baseline Depression Severity	30 days	Hamilton Depression Rating Scale

Secondary

Measure	Time frame	Description
Change from baseline respiratory rate	30 days	Change in resting respiratory rate
Change from baseline tobacco consumption	30 days	Change in daily tobacco consumption
Change from baseline heart rate	30 days	Change in resting heart rate
Change in consumption of anxiolytics	30 days	Change in daily use of anxiolytic drugs
Change from baseline alcohol consumption	30 days	Change in weekly alcohol consumption
Change from baseline blood pressure	30 days	Change in systolic blood pressure

Countries

Switzerland

Contacts

Primary ContactJan Sarlon

jan.sarlon@upk.ch+41613255381

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026